Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Lupin Australia Pty Limited

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (297)
ARTG (244)
Prescription medicine registration (23)

Date

2026 (2)
2025 (18)
2024 (49)
2023 (48)
2022 (222)
2021 (8)
2020 (33)
2019 (21)
2018 (32)
2017 (11)
2016 (10)
2014 (27)
2013 (14)
2012 (2)
2011 (16)
2010 (19)
2009 (1)
2008 (21)
2007 (5)
2001 (1)
1991 (4)

Search

Sponsor content

564 result(s) found, displaying 291 to 300

ABACAVIR/LAMIVUDINE GH 600/300 abacavir (as hydrochloride) 600 mg and lamivudine 300 mg film-coated tablet bottle pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ABACAVIR/LAMIVUDINE GH 600/300 abacavir (as hydrochloride) 600 mg and lamivudine 300 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESCITAL escitalopram (as oxalate) 5mg tablet bottle Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESCITALUPIN escitalopram (as oxalate) 5mg tablet bottle Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESCILUPIN escitalopram (as oxalate) 5mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
DULOXETINE GENERICHEALTH duloxetine (as hydrochloride) 30mg enteric capsules blister pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
DULOXETINE GENERICHEALTH duloxetine (as hydrochloride) 60mg enteric capsules blister pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESCITAL escitalopram (as oxalate) 20mg tablet bottle Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESCITAL escitalopram (as oxalate) 15mg tablet bottle Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESCITAL escitalopram (as oxalate) 10mg tablet bottle Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited

Pages

First page
Previous page
…
Page 26
Page 27
Page 28
Page 29
Current page 30
Page 31
Page 32
Page 33
Page 34
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.